-
公开(公告)号:US20110293586A1
公开(公告)日:2011-12-01
申请号:US13139482
申请日:2008-12-15
IPC分类号: A61K38/26 , C07H21/00 , C12N15/63 , C12N1/21 , C12N1/19 , C12N1/11 , C12N5/10 , C12N1/15 , A61K31/7088 , A61K48/00 , A61K35/74 , A61K35/68 , A61K36/06 , A61K35/64 , A61K35/12 , A61K36/064 , A61K36/00 , A61P9/10 , A61P3/10 , A61P9/12 , A61P3/04 , A61P9/00 , A61P3/06 , A61P29/00 , A61P1/16 , C07K14/605
CPC分类号: C07K14/605 , A61K38/00
摘要: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译: 本发明提供了用于促进体重减轻或预防体重增加以及治疗糖尿病,代谢综合征和相关疾病的材料和方法。 特别地,本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比,肽可以通过增加对GLP-1受体的选择性而介导其作用。